PuSH - Publikationsserver des Helmholtz Zentrums München

Stollenwerk, B. ; Iannazzo, S.* ; Akehurst, R.* ; Adena, M.* ; Briggs, A.* ; Dehmel, B.* ; Parfrey, P.* ; Belozeroff, V.*

A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet.

Pharmacoeconomics 36, 603-612 (2018)
Postprint Forschungsdaten DOI Verlagsversion bestellen
Open Access Green
Introduction: Etelcalcetide is a novel intravenous calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in haemodialysis patients. The clinical efficacy and safety of etelcalcetide (in addition to phosphate binders and vitamin D and/or analogues [PB/VD]) was evaluated in three phase III studies, including two placebo-controlled trials and a head-to-head study versus the oral calcimimetic cinacalcet. Objective: The objective of this study was to develop a decision-analytic model for economic evaluation of etelcalcetide compared with cinacalcet. Methods: We developed a life-time Markov model including potential treatment effects on mortality, cardiovascular events, fractures, and subjects’ persistence. Long-term efficacy of etelcalcetide was extrapolated from the reduction in parathyroid hormone (PTH) in the phase III trials and the available data from the outcomes study in cinacalcet (EVOLVE trial). Etelcalcetide was compared with cinacalcet, both in addition to PB/VD. We applied unit costs averaged from five European countries and a range of potential etelcalcetide pricing options assuming parity price to weekly use of cinacalcet and varying it by a 15 or 30% increase. Results: Compared with cinacalcet, the incremental cost-effectiveness ratio of etelcalcetide was €1,355 per QALY, €24,521 per QALY, and €47,687 per QALY for the three prices explored. The results were robust across the probabilistic and deterministic sensitivity analyses. Conclusions: Our modelling approach enabled cost-utility assessment of the novel therapy for SHPT based on the observed and extrapolated data. This model can be used for local adaptations in the context of reimbursement assessment.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
ISSN (print) / ISBN 1170-7690
e-ISSN 1179-2027
Zeitschrift PharmacoEconomics
Quellenangaben Band: 36, Heft: 5, Seiten: 603-612 Artikelnummer: , Supplement: ,
Verlag Springer
Begutachtungsstatus